KTRA · Kintara Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q3 '24 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | $0 | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.23M | - | $4.97M | $2.82M | $252.0K | - | $111.0K | $592.0K | - | $1.86M |
| SG&A | $2.30M | - | $1.76M | $4.95M | $1.96M | - | $908.0K | $1.49M | - | $1.10M |
| Total Operating Expenses | $7.53M | - | $6.73M | $3.62M | $2.21M | - | $1.02M | $2.08M | - | $2.96M |
| D&A | $23.5K | - | $21.0K | $35.0K | $34.3K | - | - | - | - | $15.0K |
| Operating Income | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | $28.0K | - | $2.00M | $1.36M | $255.1K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.54M) | - | ($7.10M) | ($5.27M) | ($2.16M) | - | ($1.02M) | ($2.01M) | - | ($2.96M) |
| EPS - Basic | ($0.13) | - | ($0.14) | ($0.21) | ($1.37) | - | ($0.24) | ($0.05) | - | ($1.83) |
| EPS - Diluted | ($0.13) | - | ($0.14) | ($0.43) | ($0.40) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q3 '24 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.30M | $3.62M | $2.70M | $8.51M | $6.22M | $12.66M | $4.91M | $6.35M | - | $216.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.95M | $3.77M | $4.13M | $3.65M | $3.08M | $3.15M | - | - | $1.87M | - |
| Current Assets | $6.98M | $4.62M | $3.50M | $12.54M | $14.33M | $19.61M | $5.53M | $6.75M | - | $783.0K |
| Total Assets | $29.70M | $27.35M | $25.70M | $34.62M | $14.64M | $19.97M | $6.20M | $7.45M | - | $1.48M |
| Current Liabilities | $6.07M | $5.92M | $8.83M | $15.17M | $4.78M | $5.33M | $2.26M | $1.34M | - | $3.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.51M | $6.42M | $8.92M | $15.17M | $4.78M | $5.37M | $2.44M | $1.52M | - | $3.50M |
| Stockholders' Equity | $23.19M | $20.93M | $16.78M | $19.45M | $9.86M | $14.59M | $3.76M | $5.92M | - | ($2.03M) |
| Retained Earnings | ($148.72M) | ($141.18M) | ($134.42M) | ($127.32M) | ($117.79M) | ($111.12M) | ($159.88M) | ($157.55M) | - | ($154.51M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q3 '24 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.41M) | - | - | - | ($1.89M) | - | - | - | - | ($1.32M) |
| Investing Cash Flow | ($48.8K) | - | - | - | ($1.15M) | - | - | - | - | - |
| Financing Cash Flow | $7.14M | - | - | - | $4.63M | - | - | - | - | ($2.0K) |
| CapEx | $48.8K | - | - | - | $42.7K | - | - | - | - | - |
| Free Cash Flow | ($4.46M) | - | - | - | ($1.93M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q3 '24 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.59 | - | - | - | 0.89 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.4% | - | -27.6% | -15.2% | -14.8% | - | -16.5% | -27.0% | - | -200.5% |
| Return on equity | -32.5% | - | -42.3% | -27.1% | -21.9% | - | -27.2% | -34.0% | - | 146.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.15 | 0.78 | 0.40 | 0.83 | 3.00 | 3.68 | 2.45 | 5.04 | - | 0.23 |
| Quick ratio | 1.15 | 0.78 | 0.40 | 0.83 | 3.00 | 3.68 | 2.45 | 5.04 | - | 0.23 |
| Cash ratio | 1.04 | 0.61 | 0.31 | 0.56 | 1.30 | 2.37 | 2.17 | 4.74 | - | 0.06 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.31 | 1.53 | 1.78 | 1.49 | 1.37 | 1.65 | 1.26 | - | -0.73 |
| Liabilities / Assets | 0.22 | 0.23 | 0.35 | 0.44 | 0.33 | 0.27 | 0.39 | 0.20 | - | 2.37 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | -248.8% | - | -253.2% | -414.7% | 27.0% | - | 70.4% | 38.4% | - | 35.6% |
| EPS growth (YoY) | 67.5% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -131.0% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 135.3% | 43.4% | 183.3% | 417.7% | - | - | 414.0% | 56.4% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Kintara Therapeutics against the 5 most active filers in the same SIC group.